Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/42746
Title: Síndrome das pernas inquietas: diagnóstico e tratamento. Opinião de especialistas brasileiros
Other Titles: Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts
Authors: Aloe, Flávio
Alves, Rosana S Cardoso
Andrade, Luiz Augusto Franco [UNIFESP]
Assis,Márcia
Bacelar, Andrea
Bezerra, Márcio
Cardoso, Francisco [UNIFESP]
Ferraz, Henrique Ballalai [UNIFESP]
Fonseca, Ronaldo Guimarães
Horta, Wagner
Haddad, Mônica Santoro
Hasan, Rosa
Mattos, James Pitágoras
Prado, Gilmar Fernandes do [UNIFESP]
Rizzo, Geraldo
Rodrigues, Nonato
Silva, Ademir Batista da [UNIFESP]
Silva, Delson Jose
Teive, Helio Afonso Ghizoni
Grupo Brasileiro de Estudos em Síndrome das Pernas Inquietas (GBE-SPI)
Universidade de São Paulo (USP)
Hosp Israelita Albert Einstein
Pratica privada
Practica Privada
Universidade Federal de Minas Gerais (UFMG)
Universidade Federal de São Paulo (UNIFESP)
UFCE
Universidade Federal de Goiás (UFG)
Keywords: restless legs syndrome
periodic leg movements
sleep
pramipexole
levodopa
dopamine agonists
gabapentine
oxycodone
clonazepam
slow release valproic acid
Issue Date: 1-Sep-2007
Publisher: Assoc Arquivos Neuro- Psiquiatria
Citation: Arquivos De Neuro-psiquiatria. Sao Paulo Sp: Assoc Arquivos Neuro- Psiquiatria, v. 65, n. 3A, p. 721-727, 2007.
Abstract: This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class 11 studies support the use of slow release valproic acid, clonazepan and oxycoclone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid.
URI: http://repositorio.unifesp.br/11600/42746
ISSN: 0004-282X
Other Identifiers: http://dx.doi.org/10.1590/S0004-282X2007000400035
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.